Enhanced Characterization of TIDES: Ensuring Patient Safety and Product Quality with NMR Spectroscopy.
Webinar Overview
As interest increases on therapeutics TIDES, regulatory agencies are calling for enhanced characterization of these modalities to ensure patient safety along with drug efficacy and quality. High-resolution analytical techniques for the structural characterization of TIDES are required to meet analytical demands, accelerate the time to market, and adopt Quality by Design (QbD) approaches. Nuclear Magnetic Resonance (NMR) spectroscopy is a critical technology to improve the characterization for TIDES. Through new probe and ultra-high field innovations, these enhancements provide deep structural insight through multi-nuclei perspectives using 1D and 2D experiments. This enables scientists to accelerate structure characterization for discovery and quality control.
November 14, 2024 | 1:25 p.m. CET
What to expect
In this presentation, you learn how enhanced structure characterization of TIDES applicable to current analytical challenges and regulatory demands are achieved using the new NMR probe and high magnetic field instrument innovations.
Key Learning Points
- Peptides and oligonucleotides (TIDES) are emerging and rapidly growing drug modalities because of their proven effectiveness that regulatory agencies are closely monitoring.
- State-of-the-art techniques, such as NMR spectroscopy, are needed to meet the demands for high-resolution structure characterization.
- New probe and instrument technologies enhance the sensitivity and resolution of NMR for TIDES to improve and accelerate analyses.
Who should attend?
Analytical or research scientists interested in improving their structural characterization of therapeutic TIDES should attend this presentation. Additionally, any NMR spectroscopists supporting drug projects should attend to keep up-to-date on the latest NMR technology that is available.
Speakers
Dr. Victor Beaumont
Strategic Market Development Specialist, Bruker BioSpin
Victor has studied and applied NMR techniques throughout his undergraduate studies at the University at Buffalo (Dr. Thomas Szyperski) and PhD program at Yale University (Dr. Patrick Loria). He later joined Pfizer as an NMR specialist for biotherapeutic structure characterization moving then to project management of analytical laboratory automation. His passion is in improving the quality of life and working efficiencies of society by facilitating and contributing high-quality scientific innovation focused on state-of-the-art NMR characterization of novel therapeutic modalities. At Bruker, he is dedicated to working with scientists in understanding the challenges and needs of the industry to expand NMR applications and technology.